Phase I Single-Center, Dose Escalation Study of D2C7-IT Administered Intratumorally Via Convection-Enhanced Delivery for Adult Patients With Recurrent Malignant Glioma
Latest Information Update: 05 Apr 2024
At a glance
- Drugs D2C7-IT (Primary)
- Indications Glioma
- Focus Adverse reactions
Most Recent Events
- 26 Mar 2024 Status changed from active, no longer recruiting to completed.
- 21 Mar 2024 Planned End Date changed from 1 Jan 2024 to 1 Jul 2024.
- 12 Jul 2022 Status changed from recruiting to active, no longer recruiting.